A Safety and Efficacy Study of RX-0201 Plus Gemcitabine in Metastatic Pancreatic Cancer

Subjects enrolled to assess safety will receive a combination of Gemcitabine plus RX-0201.
Gemcitabine will be administered prior to RX-0201 intravenously in a 30-min iv infusion dose
at 1000 mg/m2 once weekly for up to 2 cycles; each 4-week cycle consist of 3-week treatment
phase followed by 1 week resting phase. RX-0201 will be administered at 250 mg/m2/day in a
24-hour continuous intravenous infusion for up to 2 cycles; each 3-week cycle consists of
2-week treatment phase followed by a 1 week resting phase. (See schedule of
assessments)Subjects enrolled to evaluate efficacy will receive a combination of Gemcitabine
and RX-0201 as outline above for up to 4 cycles.